RNAi-mediated knockdown of relaxin decreases in vitro proliferation and invasiveness of osteosarcoma MG-63 cells by inhibition of MMP-9

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 8, 2013, Pages 1102-1109

  Ma, J F ^a   Liu, L ^a   Yang, W J ^a   Zang, L N ^a   Xi, Y M ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

Atherosclerosis (AS); Homocysteine (Hcy); Lutein; Oxidative stress

Indexed keywords

GELATINASE B; LAMIN A; LAMIN C; MATRIGEL; RELAXIN; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; NICK END LABELING; OSTEOSARCOMA CELL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR INVASION; WESTERN BLOTTING; ZYMOGRAPHY;

BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; OSTEOSARCOMA; RELAXIN; RNA INTERFERENCE;

EID: 84878538995     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. MA X, YANG Y, WANG Y, AN G, LV G. Small interfering RNA-directed knockdown of S100A4 decreases proliferation and invasiveness of osteosarcoma cells. Cancer Lett 2010; 299: 171-181.
2. SICLARI VA, QIN L. Targeting the osteosarcoma cancer stem cell. J Orthop Surg Res 2010; 5: 78.
3. SHERWOOD OD. Relaxin's physiological roles and other diverse actions. Endocr Rev 2004; 25: 205-234.
4. BATHGATE RA, IVELL R, SANBORN BM. International Union of Pharmacology LVII: recommendations for the nomenclature of receptors for relaxin family peptides. Pharmacol Rev 2006; 58: 7-31.
5. ZHAO L, ROCHE PJ, GUNNERSEN JM, HAMMOND VE, TREGEAR GW, WINTOUR EM, BECK F. Mice without a functional relaxin gene are unable to deliver milk to their pups. Endocrinology 1999; 140: 445-453.
6. GUICO-LAMM ML, SHERWOOD OD. Monoclonal antibodies specific for rat relaxin. II. Passive immunization with monoclonal ant ibodies throughout the second half of pregnancy disrupts birth in intact rats. Endocrinology 1988; 123: 2479-2485.
7. GOLDSMITH LT, WEISS G, PALEJWALA, S PLANT TM, WOJTCZUK A, LAMBERT WC, AMMUR N, HELLER D, SKURNICK JH, EDWARDS D, COLE DM. Relaxin regulation of endometrial structure and function in the rhesus monkey. Proc Natl Acad Sci U S A 2004; 101: 4685-4689.
8. SILVERTOWN JD, SYMES JC, NESCHADIM A, NONAKA T, KAO JCH, SUMMERLEE AJ, MEDIN JA. Analog of H2 relaxin exhibits antagonistic properties and impairs prostate tumor growth. FASEB J 2007; 21: 754-765.
9. SILVERTOWN JD, NG J, SATO T, SUMMERLEE AJ, MEDIN JA. H2 relaxin overexpression increases in vivo prostate xenograft tumor growth and angiogenesis. Int J Cancer 2006; 118: 62-73.
10. SILVERTOWN JD, GEDDES BJ, SUMMERLEE AJ. Adenovirus mediated expression of human prorelaxin promotes the invasive potential of canine mammary cancer cells. Endocrinology 2003; 144: 3683-3691.
11. FENG S, AGOULNIK IU, BOGATCHEVA NV, KAMAT AA, KWABI-ADDO B, LI R, AYALA G, ITTMANN MM, AGOULNIK AI. Relaxin promotes prostate cancer progression. Clin Cancer Res 2007; 13: 1695-1702.
12. BINDER C, HAGEMANN T, HUSEN B, SCHULZ M, EINSPANIER A. Relaxin enhances in-vitro invasiveness of breast cancer cell lines by up-regulation of matrix metalloproteases. Mol Hum Reprod 2002; 8: 789-796.
13. CAO WH, LIU HM, LIU X, LI JG, LIANG J, LIU M, NIU ZH. Relaxin enhances in-vitro invasiveness of breast cancer cell lines by upregulation of S100A4/MMPs signaling. Eur Rev Med Pharmacol Sci 2013; 17: 609-617.
14. HOMBACH-KLONISCH S, BIALEK J, TROJANOWICZ B. Relaxin enhances the oncogenic potential of human thyroid carcinoma cells. Am J Pathol 2006; 169: 617-632.
15. FERLIN A, PEPE A, FACCIOLLI A, GIANESELLO L, FORESTA C. Relaxin stimulates osteoclast differentiation and activation. Bone 2010; 46: 504-513.